Home  »  Market Insights   »  The Best Reason to Add Bionano Genomics Inc (BNGO)...

The Best Reason to Add Bionano Genomics Inc (BNGO) to Your Portfolio?

Biotechnology company Bionano Genomics Inc. (NASDAQ: BNGO) has seen its share price rise more than 170% in its first few weeks of 2021. BNGO’s share price rose 21.29% to $8.43 at the close on January 15. One of the factors driving company growth has been reports of doctors’ experiences of using its advanced platform to analyze solid cancers.

China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal

Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.

Simply click here and the name & trading symbol are yours.

Sponsored

Several doctors attended the Next Generation Cytogenomics Symposium and shared their experiences with the Saphyr Optical Genome Mapping System (OGM) developed by Bionano Genomics. The reports contained detailed descriptions of a number of solid tumors, including the brain, breast, liver, and eye cancer.

Saphyr provides experts with a clear understanding of the structural changes that occur in solid tumors. The use of advanced software and tools enables more accurate predictions and more targeted treatment planning while saving time and money, increasing its competitive edge against other companies in developing new approaches.

It is important to note that Bionano Genomics Inc (BNGO) raised $ 101.8 million last week in an equity placement to accelerate growth. As is the case for other biotech companies, Bionano Genomics, however, is a high-risk investment, as well. Therefore, investors can expect some volatility in the stock market in the upcoming quarters. However, in the long run, Bionano Genomics could see growth since its next-generation cancer analysis platform could become the de facto standard in next-generation medicine.

Leave a Comment

Your email address will not be published. Required fields are marked *

Related Posts

385

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

The 5 Best Inflation Stocks for 2022

100% free. stop anytime no spam

Get our free report on the stocks that we recommend for investors who want to protect their portfolios from inflation.

Receive Best Stock To Trade Before The Opening Bell

 

 

100% Free. Stop Anytime. No Spam